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Simple Summary: Neoplastic meningitis (NM) is a frequent complication of cancer and is associated
with a poor prognosis. The currently available therapies aim to alleviate symptoms and preserve
the quality of life. It comprises a multimodal approach, including surgery, intrathecal and systemic
chemotherapy, and radiotherapy. The specific treatment is individualized, based on clinical practice
guidelines and expert opinion. There are multiple clinical trials undertaken to evaluate the efficacy of
novel therapies, including targeted and immunotherapies. This article presents an updated review of
treatment approaches in NM.
Abstract: Central nervous system (CNS) metastasis from systemic cancers can involve the brain
parenchyma, leptomeninges, or the dura. Neoplastic meningitis (NM), also known by different
terms, including leptomeningeal carcinomatosis and carcinomatous meningitis, occurs due to solid
tumors and hematologic malignancies and is associated with a poor prognosis. The current management paradigm entails a multimodal approach focused on palliation with surgery, radiation, and
chemotherapy, which may be administered systemically or directly into the cerebrospinal fluid (CSF).
This review focuses on novel therapeutic approaches, including targeted and immunotherapeutic
agents under investigation, that have shown promise in NM arising from solid tumors.
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1. Introduction
Neoplastic meningitis (NM), also known as leptomeningeal metastasis or leptomeningeal
carcinomatosis, refers to the involvement of the subarachnoid space and leptomeningesarachnoid and pia mater by primary tumor spread. The incidence of NM ranges from
5–8% in patients with solid tumors to 15% in patients with hematologic malignant spread,
and it often accompanies metastases to the brain (BMs) [1]. NM has historically been
associated with a dismal prognosis of 2–4 months, and it continues to remain poor, with
patients presenting with a wide range of clinical features from simultaneous involvement
of multiple locations throughout the neuraxis [1,2]. The diagnosis of NM requires a high
index of clinical suspicion and is made by imaging with cerebrospinal fluid (CSF) studies.
The management of patients with NM has evolved tremendously over the past decade,
improving both the quality of life and survival. This narrative review highlights these
advancements in management, focusing on new therapeutic modalities, including targeted
and immunotherapies.
2. Epidemiology
The incidence of NM is around 5% in patients with metastatic cancer, with most
patients being diagnosed late in the disease course [3]. Brain metastases frequently accom-
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highlights these advancements in management, focusing on new therapeutic modalities,
including targeted and immunotherapies.
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Figure 1. The structure and composition of the brain barrier The brain barrier consists of three parts:
the blood- cerebrospinal fluid (CSF) barrier, blood–brain barrier, and CSF-brain barrier. (a) The
blood-CSF barrier is located between the blood and CSF in the ventricular choroid plexus. (b) The
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blood–brain barrier (BBB) is located between microvascular endothelial cells and the nerve cells of
the brain and spinal cord. There are intact tight junctions between capillary endothelial cells that
prevent the passage of macromolecules other than water and certain ions. The intact and continuous
capillary basement membrane is surrounded by a glial membrane of protruding astrocytes. The
BBB, main barrier that protects the CNS, prevents many macromolecules from entering the brain
and selectively pumps harmful substances out of the brain. (c) The CSF-brain barrier is located
between the CSF in the ventricles and subarachnoid space and the nerve cells of the brain and
spinal cord. Reproduced with Permission from Wang, Y., Yang, X., Li, N.J., Xue, J.X. Leptomeningeal
metastases in non-small cell lung cancer: Diagnosis and treatment. Lung Cancer. 2022;174:1–13.
doi:10.1016/j.lungcan.2022.09.013 [15].

Involvement of the leptomeninges, which comprise the arachnoid and pia mater,
allows the malignant cells to grow and reach throughout the subarachnoid space via
the CSF [16]. While present inside the CSF, the tumor cells are preserved from immune
surveillance and attack, which aids in their further proliferation, referred to as the CSF
sanctuary phenomenon [17].
There exist various means via which the tumor cells reach the CSF, with hematogenous
dissemination being the most common. Other routes include a direct extension from
pachymeningeal or dural metastases, infiltration along nerve sheaths, spread from choroid
plexus metastases, and rarely, from tumors arising within the meninges itself [18]. Cranial
nerve involvement by tumors comes in several shapes or forms, many of which give rise
to the cranial neuropathies in neoplastic meningitis and some of which contribute to the
causation of neoplastic meningitis as well (Table 1).
Table 1. Mechanisms of nerve invasion: several mechanisms of nerve involvement are known and
vary from mechanical lesions to different oncological patterns. Abbreviations: NGF, Nerve growth
factor; NCAM, Neural Cell Adhesion Molecule. Reproduced with Permission from Grisold W, Grisold
A. Cancer around the brain. Neurooncol Pract. 2014; 1(1): 13–21. doi:10.1093/nop/npt002 [19].
Type of Nerve Growth

Subgroups

Mechanical causes

Compression
Engulfing
Pushing and stretching of the nerve by
mass lesion
Direct invasion (local infiltration)
Perineural
Endoneurial
Intravascular spread
Isolated intranerval (rare)
Anterograde
Retrograde
Particular patterns:
Spread via nerve scaffolds
Dermatomal spread
Anastomotic spread from one nerve
region into another
Peripheral nerve sprouting
NGF, NCAM, other local factors
promoting nerve growth

Invasion

Metastasis
Perineurial spread

Tumor invasion—nerve growth
Growth factors
Angiosoma vs. common anatomical
distribution

Concept of metastatic distribution

Remarks

Observed experimentally

The angiosoma concept divides the skull
into 13 different angiosomas

The causation of a multitude of symptoms is attributed to various pathophysiological
mechanisms, like cerebral edema, due to BBB disruption or direct tumor involvement,
leading to cranial nerve and spinal root dysfunction. Invasion of the brain parenchyma
can interfere with circulation and cause diffuse cerebral dysfunction. Finally, increased
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intracranial pressure, due to either mass effect or flow obstruction, leads to hydrocephalus
and associated symptoms.
4. Clinical Features
NM classically has a multifocal involvement, and despite presenting with a single
symptom, a thorough neurologic evaluation reveals further sites of CNS affection. The
specific clinical symptoms are attributable to sites of invasion by leptomeningeal disease
itself, or to sequela like hydrocephalus. Headache is the most common symptom of
NM, the presenting symptom in 30–50% of patients, and can be due to either meningeal
irritation or increased intracranial pressure (ICP) [20]. An association with neck stiffness
suggests headache due to meningeal irritation, whereas accompanying symptoms of nausea
with vomiting and signs including papilledema point towards increased ICP. Various
presentations of encephalopathy are also common in NM due to hydrocephalus, seizures,
or diffuse cerebral dysfunction. This can present as disorientation, personality changes,
confusion, and forgetfulness. Seizures are observed in up to 25% of patients with NM due
to parenchymal irritation from invasion, edema, or adjacent leptomeningeal deposits [21].
The occurrence of epileptiform activity is frequently confused with plateau waves, which
occur during positional changes and are a marker of increased ICP. These can be associated
with positional headache, dizziness, presyncope, or episodes of frank syncope, and their
presence should follow a workup for increased ICP [22]. Cerebellar dysfunction is reported
in 20% of patients at presentation and can cause midline and lateral cerebellar symptoms [4].
Invasion of cranial nerves in the subarachnoid symptoms leads to a multitude of
symptoms due to cranial neuropathies. Diplopia is the most common symptom and can
be caused by the involvement of either cranial nerves III, IV, or VI [23]. Trigeminal nerve
involvement leads to sensory changes over the face, with a classic presentation of facial
numbness known as the “numb chin syndrome.” [24]. Facial and vestibulocochlear nerve
involvement leads to weakness of facial muscles and sensorineural hearing loss, respectively, and lower cranial nerve dysfunction causes dysphagia, dysarthria, and hoarseness,
due to laryngopharyngeal involvement. Spinal nerve root involvement has also been
reported, with resultant radiculopathy and cauda equina syndrome, with lower spinal
roots more frequently involved than the cervical roots. Finally, cortical signs are rarely seen
and suggest an accompanying parenchymal invasion.
5. Diagnosis
A thorough evaluation, including a complete history and physical examination, is
pertinent to identify clues of NM’s multifocal involvement. Neuroimaging studies include
a gadolinium-enhanced magnetic resonance imaging (MRI) scan of the brain and cervical,
thoracic and lumbar spine, or computed tomography (CT) scan with contrast, with the
former having greater sensitivity. However, an MRI is less specific than a CSF cytology
examination and depicts enhancing foci within the sulci, cisterns, and subarachnoid space
in the spine [25]. These findings can be accompanied by ventriculomegaly, and fluidattenuated inversion recovery (FLAIR) images depict hyperintensity due to increased
protein content in the CSF [26].
The lumbar puncture could show an elevated opening pressure, and CSF examination
typically reveals elevated protein and low glucose concentrations, lymphocytic pleocytosis. The derangement in all the parameters is uncommon; however, a completely normal
CSF examination is rare [27]. Xanthochromia may be seen with hemorrhage from the leptomeningeal deposits, primarily originating from melanoma [28]. The definitive diagnostic
finding by identifying malignant cells within the CSF carries a high specificity, but the
sensitivity is low due to sampling issues and may necessitate repeat lumbar punctures.
Immunohistochemical studies in the CSF yield may assist in diagnosing patients with NM
due to unknown primary [29].
The concentration of tumor markers may also carry relevance, as an increase with
respect to serum concentration is strongly suggestive of NM. A rise in the concentration of
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CSF tumor makers more than 2–3% of serum values is unlikely due to simple diffusion or
serum contamination unless an increased CSF albumin concentration is also present- which
indicates disruption of the BBB [30]. Novel techniques, including identifying circulating
tumor cells and cell-free DNA in CSF, carry high sensitivity and specificity and have
been increasingly used in the last few years [31]. Evaluation of CSF by flow cytometry
accords importance in the assessment of patients with suspected NM due to primary central
nervous system lymphoma or other subtypes of non-Hodgkin lymphoma with a propensity
for CNS involvement. The CSF examination reveals an elevated protein concentration,
lymphocyte-predominant pleocytosis, and decreased glucose levels, with flow cytometry
confirming the presence of malignant lymphoid cells [32].
6. Management
The management strategies for patients with neoplastic meningitis (NM) aim to improve neurologic function, prolong survival and prevent further neurologic deterioration.
A multidisciplinary tumor board is essential to deciding individual treatment strategies,
with inputs from a team of neurosurgeons, radiation oncologists, neuro-oncologists, and
medical oncologists. The treatment options are broadly categorized into systemic therapies, radiation therapies (RT), and therapies instilled directly into the CSF: intrathecal
therapies (IT).
6.1. Symptomatic Management
The development of increased intracranial pressure (ICP) is a frequent consequence
of NM, owing to the hindrance of CSF outflow via the arachnoid granulations. Medical
therapies exploited to curb the increasing ICP consist of acetazolamide to decrease the CSF
production from choroid plexus and, occasionally, hyperosmotic agents such as mannitol
and hypertonic saline to treat acute symptomatic raised ICP. Mechanical means of ICP
reduction may need to be employed in refractory cases, with the ventriculoperitoneal
shunt leading to improvements in both acute decompensation and overall survival [33,34].
Theoretical risks of seeding the tumor cells from CSF to the peritoneum exist, but the
overall benefit far outweighs the benefits of CSF redirection [35]. Seizures can be managed
with various antiepileptic drugs, with levetiracetam being an excellent first-line option,
considering its low risk of drug interactions [36]. Similar to patients with BMs, routine
prophylaxis with anti-seizure drugs is not advised, as it leads to unnecessary adverse effects
associated with these drugs.
6.2. Radiotherapy
Radiotherapy in NM serves the role of symptom palliation in managing bulky disease
and may improve subsequent penetration of systemic therapies by disturbing the blood–
brain barrier (BBB) [37]. It, however, has not demonstrated an improvement in survival.
The extent of RT is tailored according to the extent of neuraxis affected, with focal RT
preferred to ablate localized bulky metastases while limiting dose-related toxicity. Wholebrain RT (WBRT) is employed more often, especially in the setting of concomitant brain
metastases (BMs), but is associated with significant cognitive decline and toxicity, when
combined with systemic therapies. The typical regimen of WBRT delivers a radiation dose
of 30 Gy in 10 fractions, but an attenuated course is preferred for patients unable to tolerate
an increased dose or duration of treatment, commonly with 20 Gy being delivered in 4 Gy
fractions [38].
Based on disease distribution, RT can improve function rapidly in symptomatic patients with or without radiographic evidence of disease. NM leading to radiculopathies
or cauda equina syndrome causes varying pain levels, weakness, and bowel and bladder
involvement and can be effectively treated with prompt lumbosacral RT [39]. Focused
skull-base RT can manage different cranial neuropathies, with the routine dose delivered
being 30 Gy in 10 fractions. Avoiding radiation to the temporal lobe can avoid subsequent
memory deficits and is primarily pursued in patients having received WBRT in the past [40].
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Patients with diffuse cerebral involvement present with encephalopathy, and WBRT is utilized to treat NM and concomitant BMs. The subset of patients experiencing symptomatic
improvement with radiotherapy is those with a lower radiographic bulk and a shorter
duration of symptoms, with those suffering from prolonged symptoms deriving little to no
benefit [41].
The use of memantine and hippocampal avoidance techniques has shown promise
in reducing the rate of cognitive deterioration in BMs, but its role in NM remains unclear.
Finally, the use of an even more extensive approach, craniospinal irradiation (CSI), targets
a broader area theoretically but is infrequently employed in clinical practice. Other than its
significant radiation exposure to the abdominal organs, CSI destroys a considerable amount
of marrow in the vertebral bodies, making future use of immunosuppressive chemotherapy
difficult [35]. Irradiation with a proton beam instead may avoid these toxicities. A phase II
trial comparing craniospinal proton irradiation with photon-involved-field radiotherapy
recently reported favorable outcomes with the use of proton therapy in patients with solid
tumor NM. A significant improvement was noted in CNS PFS (7.5 mths vs. 6.6 mths) and
OS (9.9 mths vs. 6.0 mths) with no difference in toxicity outcomes with the use of proton
irradiation [42].
6.3. Intrathecal Chemotherapy
Intrathecal (IT) chemotherapy has the theoretical advantage of delivering anticancer
agents directly to the site of solid metastases and allowing sufficient concentration to be
administered throughout the CSF in case of diffuse metastases. However, since the diffusion
beyond the CSF is limited only to a few millimeters, IT chemotherapy is employed in nonbulky disease and to treat bulky metastases post-radiation. By avoiding the route through
BBB, IT chemotherapy allows a lower dose of cytotoxic agents to be delivered, thereby
lowering the risks of systemic toxicity. The IT chemotherapy regimens involve three phases:
high-dose induction, intermediate-dose consolidation, and low-dose maintenance [43].
The two main routes for the administration of IT chemotherapies include a lumbar
puncture (LP) or via a ventricular reservoir (e.g., Ommaya reservoir). The advantages
associated with using the Ommaya reservoir include a better distribution throughout the
CSF compartment, avoidance of repeated LPs, and thus greater ease of administration.
Ideally, A CSF flow study is conducted prior to administering IT chemotherapy to ensure
an unobstructed CSF path and optimal drug distribution. The CSF flow studies described
by Chamberlain utilized the isotopes Technetium-99 or Indium-111, and if the reports
suggested an obstruction, IT chemotherapy was not opted for [44].
The procedural risks associated with both these approaches constitute the main drawback of this treatment route. These include, but are not limited to, CNS infection, cerebral
herniation, and CSF leak [45]. The ventricular reservoirs carry additional risks, including
catheter misplacement, tip occlusion, and aseptic, chemical, or septic meningitis. Cessation of therapy with the removal of the reservoir may be required to manage these
complications. Besides, the drugs administered intrathecally have short half-lives, with concentrations declining to subtherapeutic levels in matter of hours, and complete elimination
in 1–2 days [46].
Other serious complications associated with IT chemotherapy include the occurrence
of progressive leukoencephalopathy. It typically occurs with intrathecal methotrexate
and has a chronic presentation with cognitive symptoms, incontinence, seizures, and gait
alterations. The incidence further increases upon the combination with RT, which forms the
basis of the recommendation of administering RT and IT methotrexate at least 2–3 weeks
apart. Liposomal cytarabine is a sustained-release form of the drug, which requires a
biweekly administration, and may achieve more homogenous CSF distribution than the
non-liposomal form [47]. However, it did not demonstrate increased survival or response
rates compared to IT methotrexate across a clinical trial or retrospective case review [48,49].
In 1998, Glantz and colleagues reported findings from a classic trial comparing liposomal
cytarabine versus methotrexate, both injected intrathecally. They found that while median
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survival was not significantly different, the time elapsed without symptoms or toxicity
(TWIST) was significantly higher, being 99 days for cytarabine and 28 days for methotrexate
(Table 2).
Table 2. Comparison of key results associated with liposomal cytarabine versus methotrexate,
both injected intrathecally. TWIST = time elapsed without symptoms or toxicity. n = number
of patients. Reproduced with permission from Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumors. Lancet Oncol. 2010; 11(9): 871–879.
doi:10.1016/S1470-2045(10)70034-6 [1].

Response (cytology rendered negative and
clinical condition stable or improved)
Median duration of response
Time before neurological progression
Survival directly linked to the meningitis
Median survival
Survival > 6 months
Survival > 1 year
Grade 3 toxicity
Duration of Grade 3 toxicity
TWIST

Liposomal Cytarabine (n = 31)

Methotrexate (n = 30)

p Value

8

6

0.76

39 days
58 days
343 days
105 days
13
5
24
18 days
99 days

26 days
30 days
98 days
78 days
5
2
20
11 days
28 days

0.31
0.0068
0.074
0.15
0.15
0.43
0.2
<0.05

Besides, conus medullaris syndrome with arachnoiditis occurs with liposomal cytarabine, which may be prevented to some extent by spacing IT and systemic chemotherapy
and administering corticosteroids. The occurrence of bone marrow suppression is common
with the use of various cytotoxic agents, with folinic acid rescue recommended after the
administration of methotrexate [50]. Finally, acute myelopathy, a disastrous complication
classically associated with methotrexate use, can present as quadriparesis or locked-in
syndrome. A diagnostic spinal MRI study can reveal normal findings or T2-hyperintense
lesions in the posterior columns. It may also be caused by the use of thiotepa or cytarabine
and can be differentiated from myelopathy due to tumor progression by measurement of
myelin basic protein in the CSF, which rises in case of drug-induced myelopathy.
Commonly used drugs included as part of IT chemotherapy are methotrexate, thiotepa,
topotecan, cytarabine, and sustained-release liposomal cytarabine, and thus the number of
available options is limited compared to those which can be administered systematically.
Owing to the dearth of clinical trials conducted to date, it has been difficult to conclude a
definite superiority of one agent over another. Moreover, most of the studies have been
single-arm studies, using different endpoints and not taking into account the multiple
subtypes or histologies of the primary tumor [35].
IT therapy was shown to increase survival up to 7.5 months in a cohort of patients
with NM from breast cancer upon being treated with a combinatorial regimen of RT with
IT methotrexate, cytarabine, or thiotepa [51]. In another subset of patients with NM due
to NSCLC studied by Chamberlain et al., the median survival was 5.0 months, with the
same combinatorial regimen utilized [52]. However, the results of the only randomized
clinical trial conducted to date comparing the efficacy of IT chemotherapy with systemic
chemotherapy revealed no difference in patient survival or neurologic response amongst
the groups. Boogerd et al. conducted this study on 35 patients with NM due to breast
cancer and noted an increased risk of neurotoxicity with IT chemotherapy. Finally, a
retrospective analysis by Bokstein et al. involving 104 patients with NM revealed no benefit
and an increased risk of complications with IT chemotherapy when combined with RT and
systemic chemotherapy, compared to a regimen excluding IT chemotherapy [53]. Recent
results from a phase I/II study of intrathecal trastuzumab in HER-2 positive cancer with
NM showed an OS of 8.3 months for patients with any HER-2 positive histology and
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10.5 months in HER-2 positive breast cancer [54]. Pharmacokinetic studies depicted a stable
CSF concentration of trastuzumab, suggesting promising future studies on the subject [54].
6.4. Systemic Therapy
6.4.1. Chemotherapy
The utilization of systemic chemotherapy assumes importance in treating associated
systemically active disease while avoiding cognitive decline and procedural complications
linked to WBRT and IT therapies, respectively. Systemic agents have shown some activity
due to the BBB breakdown in the NM setting, although efficacy depends heavily on tumor
subtype and histology. Some commonly used systemic chemotherapy agents utilized are
described in Table 3.
Table 3. Standard and experimental systemic chemotherapy drugs for treatment of neoplastic
meningitis. Reproduced with permission from Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumors. Lancet Oncol. 2010; 11(9): 871–879.
doi:10.1016/S1470-2045(10)70034-6 [1].
Available for
Routine Use
Methotrexate

Yes

Thiotepa

Yes

Cytarabine

Yes

Liposomal
cytarabine
Topotecan

Yes
Yes

Mafosfamide

No

Etoposide

Yes

Floxuridine

No

Diaziquone

No

Mercaptopurine

No

Busulfan

No

Induction

Consolidation

Maintenance

10–15 mg twice weekly
(for 4 weeks)
10 mg twice weekly
(for 4 weeks)
25–100 mg twice
weekly (for 4 weeks)
50 mg every 2 weeks
(for 8 weeks)
0·4 mg twice weekly
(for 6 weeks)

10–15 mg once
weekly (for 4 weeks)
10 mg once weekly
(for 4 weeks)
25–100 mg once
weekly (for 4 weeks)
50 mg every 4 weeks
(for 24 weeks)
0·4 mg once per
week (for 6 weeks)

10–15 mg once a
month
10 mg once a month

20 mg once or twice
weekly until CSF
remission
0·5 mg/day for 5 days
every other week
(for 8 weeks)

20 mg weekly

0·5 mg/day
for 5 days every
other week
(for 4 weeks)

25–100 mg once a
month

0·4 mg twice monthly
for 4 months, then
monthly thereafter
20 mg every
2–6 weeks
0·5 mg/day for 5 days
once a month

1 mg/day continued
for as long as possible
1–2 mg twice weekly
for few weeks
10 mg twice weekly for
4 weeks
5–17 mg twice weekly
for 2 weeks

Non-targeted agents like methotrexate, a dihydrofolate reductase inhibitor, have
historically been used to treat primary central nervous system lymphoma. It has also
demonstrated efficacy in treating NM originating from solid tumors like squamous cell
carcinoma (SCC) of the head and neck. The use of high-dose intravenous methotrexate
demonstrated a significant increase in survival compared to IT methotrexate, when used as
a sole treatment for managing NM, with a median survival of 13.8 mths (vs. 2.3 mths) [55].
Thiotepa, a DNA alkylating agent, does cross the BBB, but its use remains limited as an
IT agent. Systemic temozolomide, a current standard of care in treating gliomas, has not
demonstrated appreciable efficacy in managing NM. The pyrimidine analog, cytarabine,
has shown efficacy in treating CNS leukemia, especially in patients with isolated CNS
involvement [56].
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6.4.2. Targeted Therapies
With an ever-increasing knowledge of driver mutations and molecular targets, the
development of targeted therapies has been progressing at a rapid pace. Non-squamous
cell lung carcinoma harboring a mutation in epidermal growth factor receptor (EGFR) has
been successfully targeted by erlotinib, which has led to extended survival in patients with
NM [57]. Another study reported a median survival of 14 months among patients treated
with erlotinib for NM associated with NSCLC [58]. Newer EGFR tyrosine kinase inhibitors
(TKIs) such as afatinib and osimertinib have demonstrated better CNS penetration and have
a critical established role in the management of BMs from EGFR-mutated NSCLC [59,60]. A
case reported the efficacy of a combination of afatinib and cetuximab in a patient with NM
due to NSCLC, leading to the resolution of NM lesions [61]. The BLOOM study, a recently
concluded phase I clinical trial, demonstrated considerable efficacy with osimertinib, a 3rd
generation TKI, in NM arising from NSCLC. Among 18 patients with NM, five patients
(28%) had a confirmed response, and 14 patients (78%) achieved disease control upon being
evaluated by MRI imaging [62].
Regarding NM arising from NSCLC harboring mutations involving the anaplastic lymphoma kinase (ALK) gene, new-generation ALK inhibitor alectinib has shown considerable
CSF penetration and activity in NM [63,64]. The efficacy of ceritinib, another 2nd generation
ALK inhibitor, has been reported recently in NM caused by ALK-mutated NSCLC as part
of the ASCEND-7 trial. In a cohort of 18 patients with NM, the whole-body ORR was 16.7%,
with the median PFS and OS being 5.2 and 7.2 months, respectively [65]. Lorlatinib, one
of the newer ALK inhibitors, has CNS penetration, as seen by adverse effects, and case
reports show initial efficacy [66].
Mutations in human epidermal growth factor receptor 2 (HER2) have been shown to
be associated with an increased risk of CNS spread [67]. Trials involving trastuzumab, a
HER2 inhibitor, have shown good CNS response in metastatic breast cancer with spread to
the brain, but separate results with respect to response in NM are unavailable [68]. Ongoing
trials evaluating the efficacy of lapatinib, a dual EGFR, and HER2 inhibitor, in treating NM
have completed recruitment, and results are awaited (NCT02650752). In combination with
capecitabine, a 5-fluorouracil prodrug, lapatinib has also demonstrated an encouraging CNS
response in the LANDSCAPE trial studying efficacy in patients with BMs [69]. Neratinib,
a HER2-targeting tyrosine kinase inhibitor combined with capecitabine, demonstrated
promising intracranial activity in patients with HER2 overexpressing breast cancer [70].
There are case series of efficacy in leptomeningeal metastases [71]. Preliminary results from
a phase II trial evaluating the effectiveness of the combination of tucatinib-trastuzumabcapecitabine in the treatment of NM from HER2+ breast cancer have reported a median OS
of 11.9 months in a cohort of 17 patients (NCT03501979) [72]. Retrospective studies of an
antibody-drug conjugate, trastuzumab deruxtecan, in patients with HER2 breast cancer and
NM showed initial evidence of activity, and more recently, the DEBBRAH trial included
patients with both BM and NM, and the published data showed excellent responses in
patients with BM while the data for NM is awaited [73].
Mutations in v-Raf murine sarcoma viral oncogene homolog B (BRAF) are prevalent
in melanoma, with its subtype BRAFv600E being the most common subtype [74]. Three
separate case reports have described the efficacy of BRAFv600E inhibitors, dabrafenib, and
vemurafenib, in treating NM arising from melanoma. The clinical trials published so far
have focused on BMs from melanoma, but trials evaluating the efficacy of immunotherapies
in NM due to melanoma are underway (NCT02939300) (Table 4).
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Table 4. Overview of clinical trials evaluating targeted therapy in neoplastic meningitis. Original
table, updated till October 2022. Abbreviations: OS: Overall survival, PFS: Progression-free survival,
DCR: Disease control rate, DOR: Duration of response, A/E: Adverse Effects, QoL: Quality of Life.
Study

Targeted Therapy

Primary Site

Estimated
Completion

N

Primary
Endpoint (s)

Secondary
Endpoint (s)

NCT04833205

EGFR-TKI + Nimotuzumab

Lung

April 2023

30

PFS

OS, A/E

NCT04425681

Osimertinib + Bevacizumab

Lung

June 2021

20

PFS, ORR

OS, A/E

NCT04944069

Almonertinib + Bevacizumab

Lung

March 2025

69

OS

PFS, ORR, DCR, DOR

NCT04778800

Almonertinib

Lung

February 2024

60

iPFS

DCR, PFS, OS

NCT02616393

Tesevatinib

Lung

April 2018

36

ORR

PFS, OS, TTP, QoL

NCT05146219

TY-9591

Lung

December 2014

60

ORR

DCR, OS, DOR, PFS

NCT04233021

Osimertinib

Lung

July 2022

113

ORR

OS, PFS, A/E, QoL

NCT03257124

AZD-9291

Lung

December 2021

80

ORR, OS

DCR, OS,
DOR, PFS, A/E

NCT03711422

Afatinib

Lung

September 2021

25

PFS, OS, ORR

A/E

6.4.3. Immunotherapies
A myriad of immunotherapies, ranging from immune checkpoint inhibitors (ICIs)
to CAR T cell therapies, have been incorporated into the management of multiple types
of tumors. Immune checkpoint blockade, with the use of antibodies targeted against
programmed death-1 (PD1), its ligand (PD-L1), or cytotoxic T lymphocyte-associated
protein-4 (CTLA-4), leads to disinhibition of T-cells, allowing them to target tumor cells
effectively. All three categories of drugs, anti-PD1, anti-PD-L1, and anti-CTLA-4, have
demonstrated efficacy against BMs from NSCLC and melanoma [75–77].
A limited number of studies have evaluated the impact of ICIs on managing NM. A
phase II study evaluated the combination of nivolumab and ipilimumab in 18 patients
with NM and reported an OS of 44% at three months. In addition, a complete response
was observed in one patient (5.6%), with stable and progressive disease in 7 (38.9%) and
4 (22.2%) patients, respectively [78]. Multiple phase II trials are underway, and the results
depicting the efficacy of PD-1 inhibitors pembrolizumab and nivolumab are keenly awaited
(NCT02886525, NCT04729348). Meanwhile, studies involving PD-L1 inhibitors durvalumab and avelumab have been started to demonstrate safety and a tolerable dose for treating NM to inspire future studies involving variable combinations of ICIs (NCT03719768,
NCT04356222). Hendriks et al. evaluated a cohort of 1288 patients of NSCLC treated with
ICIs, among which 19 patients were observed to have NM. A PFS of 2.0 and a median OS
of 3.7 months were reported in that cohort. [79]. Finally, Geukes Foppen et al. evaluated a
series of 39 patients with NM due to melanoma and reported an abysmal prognosis even
after using ipilimumab at 15.8 weeks [80].
Other clinical trials currently ongoing related to NM due to breast cancer are evaluating the efficacy of CAR T cell therapy (HER2 CAR) and a bi-specific antibody (HER2Bi)
(NCT03696030, NCT03661424). Preliminary results from the NM cohort of patients receiving abemaciclib, a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor, in breast cancer
revealed a PFS of 5.9 months and an OS of 8.4 months [81]. Regarding the utilization
of immunotherapies to treat NM due to melanoma, two separate cohort studies have
demonstrated the use of IT interleukin-2 (IL-2) with varying chemotherapy combinations
and reported a similar survival of 7.8–7.9 months, respectively. [82,83]. Finally, intrathecal
administration of the immunotherapeutic agent nivolumab has also been attempted in a
single-arm phase I/Ib trial (NCT03025256) in patients with NM due to melanoma. Preliminary results include a median OS of 42% at six months, 30% at 12 months, and a tolerable
side effect profile, with no grade 4 or 5 toxicities [84] (Table 5).
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Table 5. Overview of clinical trials evaluating immunotherapy in neoplastic meningitis. Original table,
updated till October 2022. Abbreviations: OS: Overall survival, PFS: Progression-free survival, DLT:
Dose Limiting Toxicity, ORR: Objective Response Rate, A/E: Adverse Effects, IT: Intrathecal, CAR-T:
Chimeric Antigen Receptor T-cell, N: Number of patients. NSCLC: Non-Small Cell Lung Cancer.
Study

Type of
Immunotherapy

Type of Study

Primary
Site

N

Therapy

Outcome

NCT02886525

Immune checkpoint
inhibitor

Phase II

Multiple

102

Pembrolizumab

ORR, OS, Extracranial ORR

NCT04729348

Immune checkpoint
inhibitor

Phase II

Multiple

19

Pembrolizumab +
lenvatinib

% alive at 6 mth

NCT03719768

Immune checkpoint
inhibitor

Phase I

Multiple

16

Avelumab

Safety, DLT

NCT04356222

Immune checkpoint
inhibitor

Phase I

NSCLC

30

Durvalumab

OS, PFS, AEs

NCT03696030

CAR T cells

Phase I

Breast

39

HER-2 CAR-T cells

DLT, AEs
AEs: frequency/type/severity/duration

NCT03661424

Immunomodulator

Phase I

Breast

16

Bi-specific antibody
(HER2Bi)

NCT02308020 [81]

Immunomodulator

Phase II

Breast

7*

Abemaciclib

PFS: 5.9 mth
OS: 8.4 mth

Hendriks et al. [79]

Immune checkpoint
inhibitor

Retrospective
cohort

Lung

19

Pembrolizumab or
nivolumab

PFS: 2.0 mth
OS: 3.7 mth

Ferguson et al. [82]

Immunomodulator

Retrospective
cohort

Melanoma

178

IT IL-2, other
combinations with
chemo

OS: 7.9 mth

Glitza et al. [83]

Immunomodulator

Retrospective
cohort

Melanoma

43

IT IL − 2 ±
chemoradiotherapy

OS: 7.8 mth

Geukes Foppen
et al. [80]

Immune checkpoint
inhibitor

Retrospective
cohort

Melanoma

10 **

Ipilimumab

OS: 15.8 wks

* 7 patients in cohort with NM, 58 patients analyzed in total. ** 6 patients received ipilimumab, 39 patients
analyzed in total.

6.4.4. Other Novel Therapies
Clinical trials evaluating ANG1005, or paclitaxel trevatide, are underway among
newly diagnosed NM from breast cancer (NCT03613181). It is a taxane derivative designed
to cross the BBB and is made from three paclitaxel molecules covalently linked to Angiopep2 [85]. IT-delivered monoclonal antibodies have been used to deliver selected radiation
or therapeutic agents. This approach of targeted radioimmunotherapy has been used in
a phase I study evaluating iodine-131 labeled monoclonal antibody 3F8, targeting GD2positive NM. A sufficient intra-CSF concentration was achieved, without significant toxicity,
with three out of thirteen patients with a radiographic response [86]. A phase II study
utilizing this agent is currently underway (NCT00445965). The glycoprotein 4Ig-B7H3 is
present on various tumors, targeted by iodine-131 labeled 8H9 monoclonal antibody, and is
currently being evaluated in phase I clinical trial (NCT00089245) (Table 6).
Table 6. Overview of Clinical trials evaluating intrathecal therapies in neoplastic meningitis. Original
table, updated till October 2022. Abbreviations: OS: Overall survival, PFS: Progression-free survival,
DLT, ORR: Objective Response Rate, RR: Response Rate, N: Number of patients, NSCLC: Non-Small
Cell Lung Cancer, SCLC: Small Cell Lung Cancer.
Study

Treatment Arms
IT methotrexate

Hitchins [87]

Grossman [88]

IT methotrexate+ IT
cytosine arabinoside
IT methotrexate
IT thiotepa

Primary Site

N

Outcome
ORR: 61%

SCLC (29%), Breast (25%), 1o brain (9%),
NSCLC (7%), lymphoma (7%)

44

Breast (48%), lung (23%), lymphoma (19%)

52

ORR: 45%
OS: 15.9 weeks
OS: 14.1 weeks
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Table 6. Cont.
Study
Glantz [49]
Glantz [89]
Shapiro [90]

Treatment Arms

Primary Site

N

IT methotrexate

Breast (36%), NSCLC (10%), 1o brain (23%),
melanoma (8%), SCLC (7%)

61

Lymphoma (100%)

28

Solid tumors (80%), lymphoma (20%)

128

IT liposomal cytarabine
IT cytosine arabinoside
IT liposomal cytarabine
IT liposomal cytarabine
IT cytosine arabinoside

Outcome
RR: 20%,OS: 78 days
RR: 26%, OS: 105 days
RR: 15%, OS: 63 days
RR: 71%, OS: 99 days
PFS: 34 days
PFS: 50 days

7. Conclusions
Neoplastic meningitis remains a disease process with poor survival outcomes due to
the tumor microenvironment, the inherently aggressive nature of the neoplasm, and the
restricted delivery of therapeutic drugs due to the blood–brain barrier. Its management
remains a challenge due to limited evidence from a small number of clinical trials. This
results in various non-standardized treatment regimens, which are personalized according
to patient and source tumor characteristics. There is a need for prospective studies focusing
on selected histological tumor types and gauging the efficacy of novel therapeutics which
have become available within the last few years. The utilization of improved diagnostic
biomarkers and an understanding of the molecular differences between the primary site and
metastatic disease will lead to the development of targeted therapies. Assessment of these
drugs within clinical trials, including patients with NM as sub-groups, will help define
better therapeutic management of patients affected by leptomeningeal tumor dissemination.
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